SCHEMBL1804345

SCHEMBL1804345

Cc1cc(-c2cc(C)c(N)cc2C)on1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
USP2 O75604 1/20 0.45
MAPK1 P28482 2/20 0.41
CYP3A4 P08684 1/20 0.41
PIK3CD O00329 7/20 0.39
PIK3CG P48736 7/20 0.39
PIK3CB P42338 6/20 0.39
BRD4 O60885 1/20 0.38
UHRF1 Q96T88 1/20 0.35
KMT2A Q03164 2/20 0.35
TERT O14746 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP19A1 P11511 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
RARA P10276 1/20 0.34
RXRA P19793 1/20 0.34
RXRG P48443 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12705541 0.75 KDM4E (0.38) TSHRALDH1A1KDM4EUSP2PIK3CD
SCHEMBL6425586 0.74 ALDH1A1 (0.57) TSHRALDH1A1KDM4EUSP2MAPK1
SCHEMBL3342160 0.73 KDM4E (0.49) ALDH1A1KDM4EKMT2ACYP1A2CYP19A1
SCHEMBL3101719 0.72 CYP3A4 (0.67) TSHRALDH1A1KDM4EMAPK1CYP3A4
SCHEMBL1806303 0.71 KMT2A (0.45) TSHRALDH1A1KDM4EUSP2CYP3A4
SCHEMBL12305019 0.69 KDM4E (0.60) TSHRALDH1A1KDM4EUSP2MAPK1
SCHEMBL17203223 0.69 PIK3CD (0.50) PIK3CDPIK3CGPIK3CBKMT2A
SCHEMBL15659764 0.68 ILK (0.43) TSHRALDH1A1KDM4EUSP2MAPK1
SCHEMBL17582961 0.67 ALDH1A1 (0.36) TSHRALDH1A1KDM4EUSP2PIK3CD
SCHEMBL12305011 0.67 KDM4E (0.45) TSHRALDH1A1KDM4EUSP2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445505-B2 Pyrimidine derivatives as kinase inhibitors IRM LLC (BM) 2013-05-21 US disclosed
US-8445505-B2 Pyrimidine derivatives as kinase inhibitors IRM LLC (BM) 2013-05-21 US disclosed
US-8445505-B2 Pyrimidine derivatives as kinase inhibitors IRM LLC (BM) 2013-05-21 US disclosed
EP-2331526-A2 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-06-15 EP disclosed
US-20110112096-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS ITM LLC (BM) 2011-05-12 US disclosed
US-20110112096-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS ITM LLC (BM) 2011-05-12 US disclosed
US-20110112096-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS ITM LLC (BM) 2011-05-12 US disclosed
WO-2009158431-A2 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112096-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IGF1R, TYMP, PDXK TSHR 2020/4885ALDH1A1 618/4885KDM4E 1914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.